Systemic Platelet-Activating Factor-Receptor Agonism Enhances Non-Melanoma Skin Cancer Growth

Area of Science:

• Immunology
• Dermatology
• Oncology

Background:

• Platelet-activating factor-receptor (PAF-R) agonists are lipid mediators involved in inflammation, immunosuppression, and cancer modulation.
• Previous studies show conflicting roles of PAF-R agonists in skin cancer, with systemic administration promoting melanoma and topical application suppressing non-melanoma skin cancer (NMSC).

Purpose of the Study:

• To investigate the context-dependent effects of systemic PAF-R agonism on skin tumorigenesis, specifically NMSC and melanocytic nevus formation.
• To further understand the role of PAF-R signaling in different skin cancer types and progression.

Main Methods:

• Mice were chronically administered carbamoyl-PAF (CPAF), a systemic PAF-R agonist, under a chemical carcinogenesis protocol (DMBA/PMA).
• Tumorigenesis, including NMSC and melanocytic nevus formation, was monitored and analyzed.

Main Results:

• Systemic CPAF administration did not affect melanocytic nevus formation.
• Conversely, systemic CPAF significantly enhanced the growth of chemically induced NMSC tumors.

Conclusions:

• The route of PAF-R agonist administration critically influences its effect on skin tumor development.
• Systemic PAF-R agonism promotes NMSC growth, contrasting with its previously observed suppressive effects when applied topically.